LabCorp and GENFIT sign exclusive agreement to commercialize a novel diagnostic test for liver disease

LILLE, FRANCE; CAMBRIDGE, MA; & BURLINGTON, N.C.—Sep. 28, 2020— GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, and LabCorp® (NYSE:LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, have agreed to a five-year exclusive licensing agreement for GENFIT’s NIS4™ technology to help identify patients with at-risk non-alcoholic steatohepatitis (NASH).

New non-invasive test for lung cancer available exclusively from Labcorp

Blood-based test guides treatment decisions for patients with non-small cell lung cancer 

Tempus and LabCorp announce collaboration to accelerate clinical trial patient participation

CHICAGO & BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 16, 2020-- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, and LabCorp (NYSE: LH), a leading global life sciences company, today announced a collaboration with LabCorp’s drug development business, Covance. LabCorp will participate in Tempus's TIME Trial® Network and the companies will work together to accelerate patient enrollment for oncology clinical trials through an innovative, data-driven approach that aims to transform the clinical trial model and modernize how they are designed and executed.

Labcorp acquires clinical ambulatory laboratory business of Franciscan Missionaries of Our Lady health system

LabCorp Expands Services in Louisiana and Mississippi Through Acquisition and Creation of a Comprehensive Clinical Laboratory Relationship